Development of new blood vessels not essential to growth of lymph node metastases

June 25, 2015, Massachusetts General Hospital
Blood vessel with an erythrocyte (red blood cell, E) within its lumen, endothelial cells forming its tunica intima (inner layer), and pericytes forming its tunica adventitia (outer layer) Credit: Robert M. Hunt/Wikipedia/CC BY 3.0

While the use of antiangiogenesis drugs that block the growth of new blood vessels can improve the treatment of some cancers, clinical trials of their ability to prevent the development of new metastases have failed. Now a study from the Massachusetts General Hospital (MGH) Cancer Center may have found at least one reason why. In their paper published online in the Journal of the National Cancer Institute, an MGH research team reports finding that the growth of metastases in lymph nodes—the most common site of cancer spread—does not require new blood vessels but instead takes advantage of existing blood vessels.

"We had previously shown that antiangiogenesis therapies were ineffective in animal models of lymphatic metastasis, but there was no data to explain the mechanism behind those observations," says Timothy Padera, Ph.D., of the Steele Laboratory of Tumor Biology in the MGH Department of Radiation Oncology, senior author of the paper. "Using a novel model we developed to facilitate discoveries about the growth and spread of , we show that angiogenesis does not occur in lymph node metastases, providing a mechanism for resistance to angiogenic therapy in these situations."

For most types of solid tumors, the presence of lymph node metastases indicates a poorer prognosis and the need for chemotherapy or other systemic treatments that are delivered throughout the body. But the actual role of lymph node metastases in the spread of cancer has been controversial, Padera notes. Some experts believe that it signifies the inherent ability of the primary tumor to spread. Other investigators believe that is an essential part of the process leading to metastases in other parts of the body and that metastatic cells in the pass into the bloodstream and seed the growth of new tumors.

To follow up their previous findings that antiangiogenesis therapies could not stop the development or growth of lymph node metastases, the MGH team designed the current study. Using a of cancer that provides direct microscopic access to lymph nodes, they first found that the initiation and growth of node metastases did not involve the development of new blood vessels. They also found no increase in the levels of angiogenesis-inducing factors or in the expression of angiogenesis-related genes in metastatic lymph nodes. In fact, levels of two antiangiogenesis factors were elevated. Analysis of metastatic lymph nodes from human patients with colon or head and neck cancers also revealed no evidence of angiogenesis.

In the mouse model, treating node metastases with two angiogenesis inhibitors that have different mechanisms of action did not change the density of blood vessels or the growth of the metastases. Finally, comparing lymph node metastases from rectal cancer patients who had been treated with the angiogenesis inhibitor bevacizumab with those from patients that received no antiangiogenesis therapy found no difference in blood vessel density within the metastatic nodes. The researchers also found that lymph node metastases appear to have developed from several different tumor cells that lodged in the nodes, not from a single tumor cell as is the case with many but not all distant metastases.

"The primary implication of our findings is that, since lymph node metastases do not require the development of new , antiangiogenic therapy will not inhibit lymphatic metastasis. Other therapies need to be tested for the treatment of patients at risk for lymph node metastasis," says Padera, who is an assistant professor of at Harvard Medical School. "Now we need to answer the question of whether or not lymph node metastases actually can seed distant metastases, which would indicate how aggressively they need to be treated."

Explore further: Study finds no need for lymph node surgery in some melanomas

Related Stories

Study finds no need for lymph node surgery in some melanomas

May 30, 2015
Worldwide, people who are diagnosed with melanoma are urged to have any lymph nodes that test positive for cancer removed, but researchers said Saturday the operation doesn't necessarily help patients live longer.

Lymph nodes signal more aggressive thyroid cancer even in young patients

June 16, 2015
Patients older than age 45 with thyroid cancer that has spread to neck lymph nodes have long been considered at higher risk of dying, but the same has not been true for younger patients.

Evidence strengthens link between NSAIDs and reduced cancer metastasis

February 13, 2012
A new study reveals key factors that promote the spread of cancer to lymph nodes and provides a mechanism that explains how a common over-the-counter anti-inflammatory medication can reduce the spread of tumor cells through ...

How cancer tricks the lymphatic system into spreading tumors

May 11, 2015
Swollen lymph nodes are often the earliest sign of metastatic spread of cancer cells. Now cancer researchers and immunologists at Sweden's Karolinska Institutet have discovered how cancer cells can infiltrate the lymphatic ...

Which breast cancer patients need lymph nodes removed? Ultrasound narrows it down

February 2, 2015
Which breast cancer patients need to have underarm lymph nodes removed? Mayo Clinic-led research is narrowing it down. A new study finds that not all women with lymph node-positive breast cancer treated with chemotherapy ...

Recommended for you

What can salad dressing tell us about cancer? Think oil and vinegar

September 20, 2018
Researchers led by St. Jude Children's Research Hospital scientists have identified another way the process that causes oil to form droplets in water may contribute to solid tumors, such as prostate and breast cancer. The ...

Novel biomarker found in ovarian cancer patients can predict response to therapy

September 20, 2018
Despite months of aggressive treatment involving surgery and chemotherapy, about 85 percent of women with high-grade wide-spread ovarian cancer will have a recurrence of their disease. This leads to further treatment, but ...

Testing fluorescent tracers used to help surgeons determine edges of breast cancer tumors

September 20, 2018
A team of researchers with members from institutions in The Netherlands and China has conducted a test of fluorescent tracers meant to aid surgeons performing tumor removal in breast cancer patients. In their paper published ...

Cancer immunotherapy might benefit from previously overlooked immune players

September 20, 2018
Cancer immunotherapy—efforts to boost a patient's own immune system, allowing it to better fight cancer cells on its own—has shown great promise for some previously intractable cancers. Yet immunotherapy doesn't work ...

New way to target advanced breast cancers

September 20, 2018
A cytokine signature found in certain kinds of breast cancer cells can not only serve as a diagnostic tool for HER2-negative cancers but also offer an effective treatment target.

Understanding epilepsy in pediatric tumors

September 20, 2018
Pediatric brain tumors are characterized by frequent complications due to intractable epilepsy compared to adult brain tumors. However, the genetic cause of refractory epilepsy in pediatric brain cancer has not been elucidated ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.